Form 4: Electromed Director Stan Erickson Receives 3,000 Restricted Shares

Electromed, Inc. Director Stan K. Erickson was granted 3,000 shares of restricted common stock, scheduled to vest on June 1, 2026.

Summary

• Stan K. Erickson, a Director of Electromed, Inc. (ELMD), acquired 3,000 shares of common stock on December 1, 2025.
• These 3,000 shares are restricted stock, scheduled to vest on June 1, 2026, unless earlier accelerated or terminated.
• The transaction price for these shares was $0, indicating a grant rather than a purchase.
• Following this transaction, Stan K. Erickson directly beneficially owns 38,817 shares of common stock.
• Additionally, 1,500 shares are indirectly beneficially owned by Liberty Capital, LP, with the reporting person disclaiming beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is generally a positive signal, indicating alignment of interests and confidence in the company's future. It's a routine insider transaction, not a major operational or financial announcement, hence a moderately positive score.

Positives

• The grant of restricted stock to a director aligns their interests with those of shareholders, potentially fostering long-term commitment and performance.
• The acquisition of shares by a director can signal confidence in the company's future prospects.

Risks

• The 3,000 restricted shares are subject to vesting conditions, meaning the director's full ownership is contingent upon meeting specific terms until June 1, 2026.

Future Outlook

The 3,000 restricted shares granted to Director Stan K. Erickson are scheduled to vest on June 1, 2026, representing a future milestone for his equity compensation.

Industry Context

Insider transactions, such as the grant of restricted stock to a director, are a common practice in publicly traded companies across various industries. These grants are typically part of executive compensation packages designed to align management and director interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock as part of director compensation is a standard practice, comparable to equity incentive plans seen in medical device companies of similar market capitalization.
• The vesting schedule of approximately six months (from December 2025 to June 2026) for these restricted shares is within typical ranges for such grants, which often vary from immediate vesting to multi-year schedules depending on the company's compensation philosophy and specific grant terms.

Related Party Transactions

• Stan K. Erickson indirectly beneficially owns 1,500 shares through Liberty Capital, LP, and disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director can enhance alignment between management and shareholder interests, potentially leading to better long-term performance.
• Director (Stan K. Erickson): The grant provides an incentive for continued service and performance, with the value of the shares tied to the company's stock price.

Next Steps

• The 3,000 restricted shares held by Stan K. Erickson are scheduled to vest on June 1, 2026.

Key Dates

Keywords

Electromed, ELMD, Stan K. Erickson, Director, Restricted Stock, Stock Grant, Insider Transaction, Form 4